The popularity of Sildenafil initially drove a surge for the drug industry, but recent changes present a uncertain outlook for shareholders. Lower-cost alternatives are reducing profits, and continued patent challenges https://delilahtryx113876.timeblog.net/77067704/the-blue-pill-and-the-pharmaceutical-industry-a-precarious-investment